Skip to content

Dexamethasone

FDA-approved product (tablet, oral), marketed as Aeroseb-Dex, Decaderm, Decadron and 13 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dexamethasone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Adrenal gland disease
  • Adrenal gland hyperfunction
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • and 62 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexamethasone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • PENG vs Femoral Block for Hip Fracture Analgesia

    NCT07073209 · start 2025-07-10

    Registered record
    Registry ID
    NCT07073209
    Conditions
    Hip Fractures
    Interventions
    PENG Block Administration; Femoral Block Administration; Bupivacaine , epinephrine Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-07-10
    Completion
    2027-04
    Enrolment
    352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHip Fractures
    InterventionPENG Block Administration; Femoral Block Administration; Bupivacaine , epinephrine Dexamethasone
    PhaseNot applicable
    Registry statusRecruiting
  • Midazolam or Fentanyl as Adjuvants to Epidural Bupivacaine Plus Dexamethasone for Analgesia

    NCT06898697 · start 2025-04-01

    Registered record
    Registry ID
    NCT06898697
    Conditions
    Lumbar Spine Fixation
    Interventions
    Epidural fentanyl; epidural midazolam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-04-01
    Completion
    2025-12-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLumbar Spine Fixation
    InterventionEpidural fentanyl; epidural midazolam
    PhaseNot applicable
    Registry statusCompleted
  • The Effect of Dexamethasone Administration Route and Local Anesthetic Concentration on Pain, Inflammatory Response, and Neuromonitoring in Children Undergoing Scoliosis Correction

    NCT06789029 · start 2025-02-01

    Registered record
    Registry ID
    NCT06789029
    Conditions
    Scoliosis Idiopathic Adolescent
    Interventions
    perineural Dexamethasone; intravenous Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-02-01
    Completion
    2026-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScoliosis Idiopathic Adolescent
    Interventionperineural Dexamethasone; intravenous Dexamethasone
    PhasePhase 4
    Registry statusRecruiting
  • Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients

    NCT07425678 · start 2025-01-01

    Registered record
    Registry ID
    NCT07425678
    Conditions
    Supratentorial Tumors
    Interventions
    Scalp nerve block; Morphine; Lidocaine; Ropivacaine; Epinephrine (Adrenaline); Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-01-01
    Completion
    2025-09-30
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSupratentorial Tumors
    InterventionScalp nerve block; Morphine; Lidocaine; Ropivacaine +2 more
    PhasePhase 4
    Registry statusCompleted
  • A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

    NCT06115135 · start 2024-06-20

    Registered record
    Registry ID
    NCT06115135
    Conditions
    Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
    Interventions
    Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-20
    Completion
    2027-12-31
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma in Relapse; Multiple Myeloma, Refractory
    InterventionVenetoclax
    PhasePhase 2
    Registry statusRecruiting
  • Comparing Efficacies of Median Nerve Hydrodissection With Dexamethasone and Dextrose in Carpal Tunnel Syndrome

    NCT06400433 · start 2024-05-13

    Registered record
    Registry ID
    NCT06400433
    Conditions
    Carpal Tunnel Syndrome; Median Nerve Entrapment; Entrapment Neuropathy
    Interventions
    Ultrasound-guided median nerve hydrodissection
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-05-13
    Completion
    2024-09-30
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarpal Tunnel Syndrome; Median Nerve Entrapment; Entrapment Neuropathy
    InterventionUltrasound-guided median nerve hydrodissection
    PhaseNot applicable
    Registry statusCompleted
  • Does Intraoperative Application of Steroids Affect Early Outcomes in Patients Undergoing Endoscopic Lumbar Discectomy?

    NCT07411326 · start 2022-09-10

    Registered record
    Registry ID
    NCT07411326
    Conditions
    Lumbar Radiculopathy; Lumbar Herniated Disk
    Interventions
    Intervention Group; Control group (Normal Saline) (C)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-09-10
    Completion
    2025-01-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLumbar Radiculopathy; Lumbar Herniated Disk
    InterventionIntervention Group; Control group (Normal Saline) (C)
    PhaseNot applicable
    Registry statusCompleted
  • A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

    NCT05147493 · start 2022-04

    Registered record
    Registry ID
    NCT05147493
    Conditions
    Multiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases
    Interventions
    Isatuximab; Bortezomib; Cyclophosphamide; Dexamethasone; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-04
    Completion
    2025-02
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type +4 more
    InterventionIsatuximab; Bortezomib; Cyclophosphamide; Dexamethasone +1 more
    PhasePhase 2
    Registry statusUnknown
  • Intravitreal and Intracameral DEX in NPDR

    NCT06951087 · start 2022-01-31

    Registered record
    Registry ID
    NCT06951087
    Conditions
    Non-Proliferative Diabetic Retinopathy
    Interventions
    Dexamethasone sodium phosphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2022-01-31
    Completion
    2025-06-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Proliferative Diabetic Retinopathy
    InterventionDexamethasone sodium phosphate
    PhasePhase 3
    Registry statusEnrolling by invitation
  • Effect of Topically Administered Levobupivacaine- Fentanyl Versus Levobupivacaine- Dexamethasone Combination in the Control of Pain After Endoscopic Sinus Surgery

    NCT05145543 · start 2021-12-01

    Registered record
    Registry ID
    NCT05145543
    Conditions
    Endoscopic Sinus Surgery; Fentanyl
    Interventions
    Saline 0.9%; Levobupivacaine Hydrochloride; Fentanyl; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2022-03
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndoscopic Sinus Surgery; Fentanyl
    InterventionSaline 0.9%; Levobupivacaine Hydrochloride; Fentanyl; Dexamethasone
    PhasePhase 2 / Phase 3
    Registry statusUnknown
  • Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

    NCT05497102 · start 2021-11-08

    Registered record
    Registry ID
    NCT05497102
    Conditions
    Multiple Myeloma
    Interventions
    Lenalidomide maintenance
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-11-08
    Completion
    2025-12
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionLenalidomide maintenance
    PhasePhase 2
    Registry statusUnknown
  • A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

    NCT04939142 · start 2021-07-12

    Registered record
    Registry ID
    NCT04939142
    Conditions
    Relapsed or Refractory Multiple Myeloma
    Interventions
    SVd (Selinexor+Bortezomib+dexamethasone); Vd (Bortezomib+dexamethasone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-07-12
    Completion
    2025-10-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Multiple Myeloma
    InterventionSVd (Selinexor+Bortezomib+dexamethasone); Vd (Bortezomib+dexamethasone)
    PhasePhase 3
    Registry statusCompleted
  • Pediatric Postoperative Analgesia With Quadratus Lumborum Block(QLB) And Dexamethasone As An Adjuvant To Bupivacaine.

    NCT04963816 · start 2021-06-16

    Registered record
    Registry ID
    NCT04963816
    Conditions
    Post Operative Pain; Quadratus Lumborum Block; Pediatric; Abdominal Surgery
    Interventions
    ultrasound guided quadratus lumborum block; Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously; Bupivacaine Injection; Dexamethasone Phosphate 4 MG/ML Injectable Solution locally
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-06-16
    Completion
    2022-01-10
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Operative Pain; Quadratus Lumborum Block; Pediatric; Abdominal Surgery
    Interventionultrasound guided quadratus lumborum block; Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously; Bupivacaine Injection; Dexamethasone Phosphate 4 MG/ML Injectable Solution locally
    PhaseNot applicable
    Registry statusCompleted
  • Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

    NCT04764942 · start 2021-05-06

    Registered record
    Registry ID
    NCT04764942
    Conditions
    Recurrent Multiple Myeloma; Refractory Multiple Myeloma
    Interventions
    Carfilzomib; Dexamethasone; Pomalidomide; Quality-of-Life Assessment; Questionnaire Administration; Selinexor; X-Ray Imaging; Computed Tomography; Positron Emission Tomography; Bone Marrow Biopsy; Bone Marrow Aspiration; Biospecimen Collection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2021-05-06
    Completion
    2027-12-17
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Multiple Myeloma; Refractory Multiple Myeloma
    InterventionCarfilzomib; Dexamethasone; Pomalidomide; Quality-of-Life Assessment +8 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting
  • High Versus Low Dose of Magnesium Sulfate as Initial Tocolytic Agent for Preterm Labour in Symptomatic Placenta Previa.

    NCT04599868 · start 2020-12-01

    Registered record
    Registry ID
    NCT04599868
    Conditions
    Placenta Previa Bleeding
    Interventions
    Magnesium sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-12-01
    Completion
    2022-08-20
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlacenta Previa Bleeding
    InterventionMagnesium sulfate
    PhasePhase 2
    Registry statusCompleted